FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid cancers with RET gene mutations or fusions

Endocrine and Neuroendocrine Tumors (NET)Lung, Respiratory and Thoracic Cancer

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions

Clin Cancer Res.

Bradford D, Larkins E, Mushti SL, Rodriguez L, Skinner AM, Helms WS, Price LSL, Fourie Zirkelbach J, Li Y, Liu J, Charlab R, Reyes Turcu F, Liang D, Ghosh S, Roscoe D, Philip R, Zack-Taylor A, Tang S, Kluetz PG, Beaver JA, Pazdur R, Theoret MR, Singh H

doi: 10.1158/1078-0432.CCR-20-3558.

Lung Cancer

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.

Further Publications

Pathogenic Germline Mutations in DNA Repair Genes in Combination With Cancer Treatment Exposures and Risk of Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer

J Clin Oncol.

Qin N, Wang Z, Liu Q, Song N, Wilson CL, Ehrhardt MJ, Shelton K, Easton J, Mulder H, Kennetz D, Edmonson MN, Rusch MC, Downing JR, Hudson MM, Nichols KE, Zhang J, Robison LL, Yasui Y

doi: 10.1200/JCO.19.02760.

Lung, Respiratory and Thoracic Cancer

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial

JAMA Oncol.

Miyamoto S, Azuma K, Ishii H, Bessho A, Hosokawa S, Fukamatsu N, Kunitoh H, Ishii M, Tanaka H, Aono H, Nakahara Y, Kusaka K, Hosomi Y, Kikuchi N, Mori Y, Itani H, Hamada A, Yamada K, Okamoto H

doi: 10.1001/jamaoncol.2020.1250.

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

FDA Approval Summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy

Clin Cancer Res.

Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, Pierre V, Charlab R, Ramamoorthy A, Song P, Li F, Yu J, Manheng W, Palmby TR, Ghosh S, Horne HN, Lee EY, Philip R, Dave K, Chen XH, Kelly SL, Janoria KG, Banerjee A, Eradiri O, Dinin J, Goldberg KB, Pierce WF, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA, Pazdur R

doi: 10.1158/

Breast Cancer

FDA Approval Summary: Fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer

Clin Cancer Res

Narayan P, Osgood CL, Singh H, Chiu HJ, Ricks TK, Chow ECY, Qiu J, Song P, Yu J, Namuswe F, Gutierrez-Lugo M, Hou S, Pierce WF, Goldberg KB, Tang S, Amiri-Kordestani L, Theoret MR, Pazdur R, Beaver JA

doi: 10.1158/1078-0432.CCR-20-4557

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations

Lung Cancer.

Imai H, Kaira K, Suzuki K, Anzai M, Tsuda T, Ishizuka T, Kuwako T, Naruse I, Nemoto K, Uchino J, Morozumi N, Ishihara S, Minato K1, Hisada T

doi: 10.1016/j.lungcan.2018.10.014.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer

Lung Cancer.

Horn L, Bauml J, Forde PM, Davis KL, Myall NJ, Sasane M, Dalal A, Culver K, Wozniak AJ, Baik CS, Mutebi A, Zhang P, Wakelee HA, Johnson BE

doi: 10.1016/j.lungcan.2018.12.003.

Related content

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

Pathogenic Germline Mutations in DNA Repair Genes in Combination With Cancer Treatment Exposures and Risk of Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial

Recent Developments in Metastatic Breast Cancer

FDA Approval Summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy

FDA Approval Summary: Fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer

A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations

Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer